Arrowstreet Capital’s Arena Pharmaceuticals Inc ARNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-8,732
| Closed | -$812K | – | 1640 |
|
|
2021
Q4 | $812K | Buy |
+8,732
| New | +$575K | ﹤0.01% | 1200 |
|
|
2021
Q2 | – | Sell |
-285,115
| Closed | -$19.8M | – | 2382 |
|
|
2021
Q1 | $19.8M | Sell |
285,115
-180,395
| -39% | -$13.9M | 0.03% | 596 |
|
|
2020
Q4 | $35.8M | Buy |
465,510
+441,610
| +1,848% | +$33.1M | 0.05% | 378 |
|
|
2020
Q3 | $1.79M | Buy |
+23,900
| New | +$1.59M | ﹤0.01% | 1609 |
|
|
2020
Q1 | – | Sell |
-155,628
| Closed | -$7.07M | – | 2210 |
|
|
2019
Q4 | $7.07M | Buy |
+155,628
| New | +$7.36M | 0.02% | 746 |
|
|
2019
Q3 | – | Sell |
-80,871
| Closed | -$4.74M | – | 1785 |
|
|
2019
Q2 | $4.74M | Buy |
+80,871
| New | +$4.18M | 0.01% | 656 |
|
|
2018
Q2 | – | Sell |
-11,057
| Closed | -$437K | – | 1373 |
|
|
2018
Q1 | $437K | Buy |
+11,057
| New | +$430K | ﹤0.01% | 971 |
|
|
2014
Q3 | – | Sell |
-27,839
| Closed | -$1.63M | – | 1160 |
|
|
2014
Q2 | $1.63M | Buy |
+27,839
| New | +$1.75M | 0.01% | 632 |
|
|
2013
Q4 | – | Sell |
-5,683
| Closed | -$299K | – | 1333 |
|
|
2013
Q3 | $299K | Sell |
5,683
-2,133
| -27% | -$143K | ﹤0.01% | 856 |
|
|
2013
Q2 | $602K | Buy |
+7,816
| New | +$638K | ﹤0.01% | 611 |
|
Arrowstreet Capital's ARNA Position: Q1 2022 in Review
Arrowstreet Capital sold out of Arena Pharmaceuticals Inc (ARNA) in Q1 2022, closing a stake of 8,732 shares — an estimated $812K sold.
Arrowstreet Capital first reported a position in ARNA in Q2 2013 and held it in 10 quarters. The position peaked at $35.8M in Q4 2020. 1 fund tracked by Wall St. Rank holds ARNA as of Q1 2022.
- Arrowstreet Capital reported no remaining Arena Pharmaceuticals Inc position as of Q1 2022 after selling out during the quarter.
- Arrowstreet Capital sold 8,732 Arena Pharmaceuticals Inc shares in Q1 2022, an estimated $812K.
- Arrowstreet Capital first reported a position in Arena Pharmaceuticals Inc in Q2 2013 and held it in 10 quarters.
- Arrowstreet Capital's Arena Pharmaceuticals Inc position peaked at $35.8M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q1 2022.
Based on Arrowstreet Capital's 13F filing for Q1 2022, filed 13 May 2022.